TuHURA Biosciences, Inc./NVHURA
What TuHURA Biosciences, Inc./NV does.
We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to “trick” the body’s immune system to attack tumor cells by making tumor cells look like bacteria. Our lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. In June 2025, we initiated a single randomized placebo-controlled Phase 3 registration trial of administered as an adjunctive therapy to Keytruda ® (pembrolizumab) in first line treatment for patients with advanced or metastatic Merkel cell carcinoma who are checkpoint inhibitor naïve utilizing the FDA’s accelerated approval pathway.
In addition to our IFx technology platform, in June 2025 we acquired the rights to TBS-2025, a novel VISTA-inhibiting monoclonal antibody formerly known as KVA1213, through our acquisition of Kineta, Inc. (“Kineta”) on June 30, 2025. VISTA (otherwise referred to as V-domain Ig suppressor of T cell activation) is an immune checkpoint highly expressed on myeloid cells that is believed to be a strong driver of immunosuppression in the tumor microenvironment and is believed to be a primary mechanism by which leukemic blasts escape immune recognition contributing to low response rates and high rates of recurrence in acute myeloid leukemia, or AML. Following our acquisition of Kineta, we are currently planning on investigating TBS-2025 in a Phase1b/2 trial in patients with r/r mut NPM1AML.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $0 |
| Net income | — | — | — | -$29.3M | -$21.7M | -$30.1M |
| Free cash flow | — | — | — | -$12.0M | -$14.8M | -$27.7M |
More on HURA.
- TuHURA Biosciences, Inc./NV summary
- TuHURA Biosciences, Inc./NV financial statements
- TuHURA Biosciences, Inc./NV key metrics
- TuHURA Biosciences, Inc./NV health scores and style box
- TuHURA Biosciences, Inc./NV earnings
- TuHURA Biosciences, Inc./NV dividends
- TuHURA Biosciences, Inc./NV valuation
- TuHURA Biosciences, Inc./NV ownership and insiders
- TuHURA Biosciences, Inc./NV peers
Figures from TuHURA Biosciences, Inc./NV's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.